Lundbeck and Otsuka update on European launch of Abilify Maintena

17 March 2014

Danish CNS drug specialist Lundbeck (LUN: CO) and Japanese drugmaker Otsuka Pharmaceutical’s (TYO: 4768) European subsidiary today announced the launch of schizophrenia drug Abilify Maintena (aripiprazole) in Europe following approval by the European Commission last year (The Pharma Letter November 21, 2013).

Abilify Maintena is now available in a number of European countries and is progressing through the various health care authorities that provide access to patients. Denmark is the first European country where Abilify Maintena is fully reimbursed and accessible to people with schizophrenia, and more than 10 markets are expected to launch by the end of 2014, the companies noted.

Abilify Maintena (aripiprazole) is an intramuscular (IM), once-monthly injectable formulation for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK